Article thumbnail
Location of Repository

The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells

By Natalia Martinez, Bettina Drescher, Heidemarie Riehle, Claire Cullmann, Hans-Peter Vornlocher, Arnold Ganser, Gerhard Heil, Alfred Nordheim, Jürgen Krauter and Olaf Heidenreich


BACKGROUND: The fusion protein RUNX1-CBFA2T1 associated with t(8;21)-positive acute myeloid leukaemia is a potent inhibitor of haematopoetic differentiation. The role of RUNX1-CBFA2T1 in leukaemic cell proliferation is less clear. We examined the consequences of siRNA-mediated RUNX1-CBFA2T1 depletion regarding proliferation and clonogenicity of t(8;21)-positive cell lines. METHODS: The t(8;21)-positive cell line Kasumi-1 was electroporated with RUNX1-CBFA2T1 or control siRNAs followed by analysis of proliferation, colony formation, cell cycle distribution, apoptosis and senescence. RESULTS: Electroporation of Kasumi-1 cells with RUNX1-CBFA2T1 siRNAs, but not with control siRNAs, resulted in RUNX1-CBFA2T1 suppression which lasted for at least 5 days. A single electroporation with RUNX1-CBFA2T1 siRNA severely diminished the clonogenicity of Kasumi-1 cells. Prolonged RUNX1-CBFA2T1 depletion inhibited proliferation in suspension culture and G1-S transition during the cell cycle, diminished the number of apoptotic cells, but induced cellular senescence. The addition of haematopoetic growth factors could not rescue RUNX1-CBFA2T1-depleted cells from senescence, and could only partially restore their clonogenicity. CONCLUSIONS: RUNX1-CBFA2T1 supports the proliferation and expansion of t(8;21)-positive leukaemic cells by preventing cellular senescence. These findings suggest a central role of RUNX1-CBFA2T1 in the maintenance of the leukaemia. Therefore, RUNX1-CBFA2T1 is a promising and leukaemia-specific target for molecularly defined therapeutic approaches

Topics: Research Article
Publisher: BioMed Central
Year: 2004
DOI identifier: 10.1186/1471-2407-4-44
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
  2. (1998). Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol
  3. (2000). Akashi K: AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
  4. (2002). AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res
  5. (2003). Aulitzky WE: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood
  6. (2003). Behre G: The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood
  7. (1982). Beta-galactosidase--an indicator of the maturational stage of mouse and human mononuclear phagocytes.
  8. (2002). Borkhardt A: Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene
  9. (2003). BR: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol
  10. Cells - A Laboratory Manual.
  11. (1995). Chihara K: Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression.
  12. (2004). Darley RL: Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia
  13. (2004). DePinho RA: Telomeres, stem cells, senescence, and cancer.
  14. (2001). DG: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med
  15. (2004). Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence?
  16. (1992). Drabkin H: Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood
  17. (2003). Eder Matthias: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood
  18. (1998). ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
  19. Gene silencing by RNAi in mammalian cells. Current protocols in molecular biology Edited by: Ausubel FM,
  20. (2002). Greaves M: In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood
  21. (2001). Hiebert SW: ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol
  22. (2001). Hinds PW: Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol
  23. (2003). Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells.
  24. (2000). Inducible chromosomal translocation of AML1 and ETO genes through Cre/ loxP-mediated recombination in the mouse. EMBO Rep
  25. (1999). Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.
  26. (1999). Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res
  27. (1991). Kamada N: Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood
  28. (2003). Killing the messenger: short rnas that silence gene expression. Nat Rev Mol Cell Biol
  29. (2002). Klug CA: Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol
  30. (2000). Lam EW: Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1.
  31. (2001). Lo Coco F, Nervi C: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res
  32. (2003). MH: An activated receptor tyrosine kinase, TEL/PDGF{beta}R, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
  33. (2000). Nimer SD: Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein.
  34. (2003). Nimer SD: Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood
  35. (2002). Nimer SD: The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood
  36. (1999). Nimer SD: The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene
  37. (2003). O: The Apparent Uptake of Fluorescently Labeled siRNAs by Electroporated Cells Depends on the Fluorochrome. Oligonucleotides
  38. (2000). Pelicci PG: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature
  39. (2003). PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol
  40. (2003). RL: The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood
  41. (2003). RNA interference (RNAi) in hematology. Ann Hematol
  42. (2002). RNA interference.
  43. (2001). Short 5'-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. Curr Biol
  44. (2002). Stocking C:
  45. (2000). SW: PML is induced by oncogenic ras and promotes premature senescence. Genes Dev
  46. (1998). SW: The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol
  47. (2002). SW: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med
  48. (1993). The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
  49. (2001). Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate.
  50. (2003). Vornlocher HP, Nordheim A: AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood
  51. (2004). Weinberg RA: When cells get stressed: an integrative view of cellular senescence.
  52. (2002). Zamore PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science
  53. (2000). Zhang DE: Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood
  54. (2001). Zhang DE: Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.